Real-World Safety and Effectiveness of Infliximab in 255 Patients with Intestinal, Neurological, and Vascular Behçet’s Disease: A Post-Marketing Surveillance
These results confirmed the safety and effectiveness of infliximab in clinical practice in 255 patients with intestinal BD, NBD, and VBD. There were no new safety concerns.
Authors
- M. TASHIRO
- Toshifumi Hibi∥ (ORCID: https://orcid.org/0000-0002-6256-1204)
- Yoshiaki Ishigatsubo (ORCID: https://orcid.org/0000-0002-2908-1452)
- Shunsei Hirohata (ORCID: https://orcid.org/0000-0003-1911-7383)
- Tadakazu Hisamatsu (ORCID: https://orcid.org/0000-0002-1178-3536)
- Hirotoshi Kikuchi (ORCID: https://orcid.org/0000-0002-1864-1098)
- Yutaka Susuta (ORCID: https://orcid.org/0000-0003-1621-9261)
- Mitsuhiro Takeno (ORCID: https://orcid.org/0000-0002-9212-7046)
- Naomi Mizuno (ORCID: https://orcid.org/0000-0002-1326-9792)
- Noriko Sato (ORCID: https://orcid.org/0000-0003-2660-0808)
Institutions
- Kyorin University (JP)
- Nippon Medical School Musashi Kosugi Hospital (JP)
- Kitasato Institute Hospital (JP)
- Mitsubishi Tanabe Pharma Corporation
- Kitasato University (JP)
- Teikyo University (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1007/s12325-024-02993-9
- Citations
- 9
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 4.85
Funders
- Mitsubishi Tanabe Pharma Corporation